Baker McKenzie Switzerland advised certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), a longstanding investor in Santhera Pharmaceuticals (SIX: SANN, “Santhera”), on its investment and commitment of an additional CHF 10 million via a new three-year convertible bond to support Santhera for the global reach expansion of AGAMREE® (vamorolone), a treatment for Duchenne muscular dystrophy. This financing is entered into in conjunction with an USD 13 million royalty monetization between Santhera and R-Bridge. Under the agreement, Highbridge provides an additional CHF 10 million to Santhera via a newly issued convertible note. The instrument also exchanges, at parity, the existing CHF 7 million convertible bond that was previously scheduled to mature on 30 September 2025. The new convertible bond has a three-year maturity, with a conversion…
